BLUE250117P12500
- 9.24
- 0.000.00%
bluebird bio Newsroom
RBC Adjusts Price Target on Bluebird Bio to $8 From $80 Amid Reverse Stock Split, 'Limited Cash Runway,' Keeps Sector Perform, Speculative Risk
Analysts Offer Insights on Healthcare Companies: Cencora (COR) and Bluebird Bio (BLUE)
Barclays Maintains Bluebird Bio(BLUE.US) With Buy Rating, Maintains Target Price $40
Barclays Maintains Bluebird Bio(BLUE.US) With Buy Rating, Maintains Target Price $40
Barclays Maintains Bluebird Bio(BLUE.US) With Buy Rating, Maintains Target Price $40
Bluebird Bio Is Maintained at Overweight by Barclays
Bluebird Bio Analyst Ratings
Barclays Maintains Bluebird Bio(BLUE.US) With Buy Rating, Maintains Target Price $40
Wells Fargo Maintains Bluebird Bio(BLUE.US) With Hold Rating, Maintains Target Price $2
Analysts Offer Insights on Healthcare Companies: Benitec Biopharma (BNTC), Bluebird Bio (BLUE) and AC Immune SA (ACIU)
Bluebird Bio Is Maintained at Overweight by Barclays
Bluebird Bio Analyst Ratings
A Quick Look at Today's Ratings for Bluebird Bio(BLUE.US), With a Forecast Between $0.5 to $2
Bluebird Bio Downgraded to Underweight From Neutral at JPMorgan
J.P. Morgan Maintains Bluebird Bio(BLUE.US) With Hold Rating
Bluebird Bio's Restructuring Efforts and Financial Outlook: A Cautious Hold Rating
Bluebird Bio Is Maintained at Equal-Weight by Wells Fargo
Bluebird Bio Analyst Ratings
Wells Fargo Maintains Bluebird Bio(BLUE.US) With Hold Rating, Cuts Target Price to $2
Maintaining Hold on Bluebird Bio: Balancing LYFGENIA's Promise Against Financial and Operational Hurdles